The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza

International Journal of Adolescent Medicine and Health

Volumn 21, Issue 1, 2009, Pages 79-89

  Casscells, S Ward ^b   Granger, Elder ^b   Kress, Amii M ^b   Linton, Andrea ^a  

^a Office of the Assistant Secretary of Defense (Health Affairs)   (United States)

^b NONE

Author keywords

Oseltamivir; Pediatric influenza; US Department of Defense

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ADJUSTMENT DISORDER; ADOLESCENT; ADULT; AGE; ANXIETY DISORDER; ARTICLE; CHILD; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CONVULSION; DEPRESSION; DISEASE ASSOCIATION; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; ENCEPHALITIS; FEMALE; HALLUCINATION; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MENTAL DISEASE; MOTOR DYSFUNCTION; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; RISK ASSESSMENT; SCHOOL CHILD; SEIZURE; SEX DIFFERENCE; SOCIAL STATUS; STROKE; TREATMENT OUTCOME; UNITED STATES; CHEMICALLY INDUCED; CHILD WELFARE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; INFANT; INFLUENZA, HUMAN; MULTIVARIATE ANALYSIS; NEUROLOGIC DISEASE; PSYCHOMETRY; PSYCHOSIS; RETROSPECTIVE STUDY; RISK; RISK FACTOR; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; FEMALE; HUMANS; INFANT; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NERVOUS SYSTEM DISEASES; ODDS RATIO; OSELTAMIVIR; PSYCHOMETRICS; PSYCHOSES, SUBSTANCE-INDUCED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65549115927     PISSN: 03340139     EISSN: None     Source Type: Journal    
DOI: 10.1515/IJAMH.2009.21.1.79     Document Type: Article

References (16)

1. Moscona A. Medical management of influenza infection. Annu Rev Med 2008;59:397-413.
2. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-33.
3. Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of healthcare services in children with clinically diagnosed influenza. Curr Med Res Opin 2007;23(3):523-31.
4. Singh S. Barghoom J, Bagdonas A, Adler J, Treanor J, Kinnersley N, et al. Clinical benefits with oseltamivir in treating influenza in adult populations: results of a pooled and subgroup analysis. Clin Drug Investig 2003;23 (9):561-9.
5. Hama R. Presented at the 37th annual meeting of the Japanese Society for Pediatric Infectious Diseases, 2005.
6. [No authors listed] New concerns about oseltarnivir. Lancet 2007;369(9567): 1056. Editorial.
7. Department of Health and Human Services, Public Health Service, Food and Drug Administration Center for Drug Evaluation and Research. Tamiflu safety update, 2007. Available at: http://www.fda.gov/ohnns/dockets/ac/ 07/slides/2007-4325s2_04_Tamiflu,%20Lewis,%20MD%20(FDA).pdf. Accessed 7 March 2008.
8. Wilcox MA. Oseltamivir therapy appears not to affect the incidence of neuropsychiatric adverse events in influenza patients. Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2007.
9. Blumentals WA, Song X. The safety of oseltamivir in patients from influenza: analysis of healthcare claims from six influenza seasons. MedGen Med 2007;9(4):23.
10. Okumura A, Kubota T, Kato T, Morishima T. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J 2006; 25:572.
11. Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidemiol Drug Saf 2004;13:227-37.
12. Department of Health and Human Services, Public Health Service, Food and Drug Administration Center for Drug Evaluation and Research. Tamiflu pediatric adverse events: questions and answers. Available at http://www.fda.gov/cder/drug/infopage/tamiflu/QA20051117.htm. Accessed 8 March 2008.
13. Johann -Liang, R.; Mosholder, A. Pediatric Advisory Committee Meeting November 16, 2006: Tamiflu[R] (oseltamivir) Safety Update. Division of Drug Risk Evaluation FDA Center for Drug Evaluation and Research. Available at: http://www.fda.gov/ohrms/dockets/AC/06/slides/ 2006-4254s_09_Johann-Liang_Tamiflu.ppt. Accessed 7 March 2008.
14. Nordstrom BL, Oh K, Sacks ST, L'Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. Antivir Ther 2004;9:187-95.
15. U.S. Department of Health and Human Services. HHS Pandernic Influenza Plan Supplement? Antiviral Drug Distribution and Use. Available at: http://www.hhs.gov/pandemicflu/plan/sup7.html. Accessed 14 Mar 2007.
16. Sin ger AC, Nunn MA, Gould EA, Johnson AC. Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect 2007; 115(1):102-6.